MeiraGTx, LLC

Quick facts

Phase 1 pipeline

• AAV2hAQP1 · Ophthalmology
  AAV2-mediated gene therapy targeting aquaporin-1

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• MeiraGTx, LLC portfolio CI brief
• MeiraGTx, LLC pipeline updates RSS